Laura Wörmeyer

Congenital Hyperinsulinism in Humans and Insulin Secretory Dysfunction in Mice Caused by Biallelic DNAJC3 Variants

Alena Welters, Oliver Nortmann, Laura Wörmeyer, Clemens Freiberg et autres

The BiP co-chaperone DNAJC3 protects cells during ER stress. In mice, the deficiency of DNAJC3 leads to beta-cell apoptosis and the gradual onset of hyperglycemia. In humans, biallelic DNAJC3 variants cause a multisystem disease, including early-onset diabetes mellitus. Recently, hyperinsulinemic hypoglycemia (HH) …

de (code pays fourni par la source)

The N-Methyl-D-Aspartate Receptor Antagonist Dextromethorphan Improves Glucose Homeostasis and Preserves Pancreatic Islets in NOD Mice

Laura Wörmeyer, Oliver Nortmann, Anna B. Hamacher, Celina Uhlemeyer et autres

Abstract For treatment of type 1 diabetes mellitus, a combination of immune-based interventions and medication to promote beta-cell survival and proliferation has been proposed. Dextromethorphan (DXM) is an N-methyl-D-aspartate receptor antagonist with a good safety profile, and to date, preclinical and clinical …

de (code pays fourni par la source)

Selective Inhibition of N-Methyl-d-aspartate Receptors with GluN2B Subunit Protects β Cells against Stress-Induced Apoptotic Cell Death

Anne Gresch, Héctor Noguera Hurtado, Laura Wörmeyer, V De Luca et autres

de (code pays fourni par la source)

Peripherally active dextromethorphan derivatives lower blood glucose levels by targeting pancreatic islets

O Scholz, Silke Otter, Alena Welters, Laura Wörmeyer et autres

de, si (code pays fourni par la source)

Preclinical studies to treat diabetes mellitus using novel DXM derivatives

O Scholz, Silke Otter, Alena Welters, Laura Wörmeyer et autres

Issue The over-the-counter drug dextromethorphan (DXM) shows anti-diabetic and islet cell-protective effects in vitro and in vivo, without inducing hypoglycemia. However, DXM is able to pass the blood-brain barrier (BBB) and potential CNS-related side effects limit its use as anti-diabetic drug. We …

de, si (code pays fourni par la source)

Langzeiteffekte des NMDAR-Antagonisten Dextromethorphan in einem Mausmodell für den Typ 1 Diabetes mellitus

Alena Welters, Laura Wörmeyer, Silke Otter, O Scholz et autres

Hintergrund: Betazelldysfunktionen und die durch Betazelltod hervorgerufene progressive Reduktion funktionaler Betazellmasse haben eine zentrale Bedeutung für die Entstehung und das Fortschreiten der Diabeteserkrankung. Unsere Arbeitsgruppe hat kürzlich zeigen können, dass der N-Methyl-D-Aspartat-Rezeptor (NMDAR) Antagonist Dextromethorphan (DXM) selektiv die glukosestimulierte Insulinsekretion steigert, die …

de (code pays fourni par la source)

NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions

Alena Welters, C. Alex Kluppel, Jessica Mrugala, Laura Wörmeyer et autres

Diabetes mellitus is characterized by chronically elevated blood glucose levels accelerated by a progressive decline of insulin-producing β-cells in the pancreatic islets. Although medications are available to transiently adjust blood glucose to normal levels, the effects of current drugs are limited when …

de (code pays fourni par la source)